§ — Market briefing
A $1.2 billion category, on a 9.1% CAGR through 2034.
An editorial briefing on the global medical-grade honey market — size, segments, channels, end-users, structural drivers and the competitors that matter — with the caveats they deserve.
§ I — Headline
The category at a glance.
$1.2B
Global market
Base year 2025
$2.6B
Forecast value
2034
9.1%
CAGR
2026–2034
47.8%
Wound-care share
of applications, 2025
§ II — Trajectory
Size & forecast, 2019 → 2034.
Historical growth has compounded at ~7%; analysts model an acceleration to 9.1% as wound-care reimbursement broadens and Asia Pacific scales.
§ III — Regional outlook
North America leads in dollars. Asia Pacific compounds fastest.
North America
≈ $458M
38.2%
United States dominates; Medicare/Medicaid coverage of Class II honey dressings; ~6.7M Americans living with DFUs and pressure injuries annually.
Europe
≈ $344M
28.7%
UK, Germany, Netherlands, Scandinavia. NHS endorsement of Medihoney and L-Mesitran; MDR EU 2017/745 streamlining clinical approvals.
Asia Pacific
≈ $258M
21.5%
Fastest-growing region — ~11.3% CAGR. AU/NZ as primary Manuka producers; rapid diabetic-population growth in China and India.
Latin America
≈ $77M
6.4%
Brazil and Mexico are the primary markets; biodiversity opens specialist therapeutic-honey opportunities.
Middle East & Africa
≈ $62M
5.2%
UAE and Saudi Arabia leading on the back of healthcare modernisation and high diabetes prevalence.
§ IV — Product & application
Manuka still 61% of value — but adjacent honeys grow faster.
Manuka honey
61.4%≈ $738M (2025)
Underpinned by MGO documentation, NPA grading and Molan Gold certification, and dominance of Comvita Medihoney and Manuka Health in hospital formularies. Premium retail $25–$120 per 250 g jar.
Other medical-grade honey
38.6%10.4% CAGR
Multifloral, Tualang, Sidr, Gelam, buckwheat. Greater supply availability, lower raw cost, growing clinical evidence (Tualang for burns and oral mucositis at Universiti Sains Malaysia).
| Application | Share 2025 | CAGR 26–34 | Key driver | Primary end-user | Top channel |
|---|---|---|---|---|---|
| Wound care | 47.8% | 8.8% | Chronic wound prevalence | Hospitals & clinics | Hospitals |
| Skin care | 20.3% | 10.7% | Cosmeceutical demand | Homecare & retail | Online stores |
| Cough & throat | 14.6% | 9.3% | Respiratory health awareness | Consumer retail | Retail pharmacies |
| Digestive health | 10.5% | 9.8% | Prebiotic recognition | Consumer retail | Online stores |
| Oral, ear, ophthalmic, vet | 6.8% | — | Adjacent indications | Mixed | Mixed |
§ V — Channel & end-user
Hospitals procure. Online compounds.
Distribution channel
Hospitals
39.6%Wound care, burn units, surgical wards. GPO and tender procurement; highest-value channel.
Retail pharmacies
27.4%Strong in UK, Australia and Germany. OTC after clinical recommendation.
Online stores
22.1%Fastest-growing — ~14.2% CAGR. DTC wellness, e-pharmacy, and homecare buyers.
Specialty / direct
10.9%Health-food, wellness clinics, naturopathic practitioners.
End-user
Hospitals
44.2%Complex wounds, surgery, burns, infection control; formulary-driven procurement.
Clinics
25.7%Outpatient wound care, dermatology, podiatry, primary care.
Homecare
21.6%Highest end-user CAGR ~12.8%. Decentralisation of wound care to community settings.
LTC, hospice, military
8.5%Pressure ulcers and chronic skin conditions in long-term care drive incremental demand.
§ VI — Growth drivers
Four structural tailwinds, in order of weight.
- 01
Chronic wounds & diabetes
537M+ adults with diabetes in 2025, projected 780M+ by 2045 (IDF). 15–25% lifetime DFU risk. Chronic wounds cost the US healthcare system >$96B/year. Honey dressings sit at $8–$45/unit with favourable cost-effectiveness.
- 02
Antimicrobial resistance
AMR is responsible for ~1.27M deaths/year globally; ~33,000/year in the EU; ~2.8M MRSA infections/year in the US. Honey's multi-mechanistic action is structurally hard to resist. Endorsed by WUWHS and EWMA wound-care guidelines.
- 03
Wellness & natural-health spend
$65B+ global natural-health products market in 2025. Premium NPA / MGO Manuka brands command shelf space across pharmacy and DTC. Skin care, lozenges and syrups expanding the non-wound base post-COVID.
- 04
Regulatory & evidence base
FDA Class II clearance for Medihoney; TGA registration of multiple Manuka products; CE marking under MDR. NICE (UK) and the Australian Wound Management Association both endorse honey-based dressings for specific wound types.
§ VII — Opportunities & threats
Where the upside sits — and where it can be lost.
+ Opportunities
- +
New clinical indications
Phase II/III trials in oral mucositis (head & neck cancer, ~550k new cases/year), post-surgical site management and periodontal disease.
- +
Composite next-gen dressings
Honey + silver nanoparticles, hyaluronic acid, collagen scaffolds, NPWT-compatible formats — premium positioning, higher reimbursement.
- +
Dermatology & women's health
Acne, eczema, psoriasis, anti-aging — and emerging research in recurrent bacterial vaginitis.
- +
Emerging-market DTC
Southeast Asia, India, LATAM, Sub-Saharan Africa — large health-conscious populations reachable at low distribution cost via e-commerce.
— Threats
- −
Adulteration & quality fraud
Independent testing has periodically found commercial Manuka with MGO levels below stated NPA rating, particularly in gray-market e-commerce.
- −
Synthetic & biologic alternatives
Silver dressings, cadexomer iodine, growth-factor therapies and bioengineered skin substitutes compete for formulary slots.
- −
Cost barrier in price-sensitive markets
Premium Manuka pricing limits access in much of Asia, LATAM and Africa where public funding is constrained.
- −
Supply concentration
~85% of certified Manuka comes from New Zealand. Climate, biosecurity (Varroa) and hive-placement competition introduce price volatility (raw NZD 25–85/kg in 2025).
- −
Regulatory complexity
Intersection of food and medical-device regulation across the US, EU and China demands ongoing regulatory-affairs investment.
§ VIII — Competitive landscape
Top five players hold ~42% of revenue.
Moderately fragmented. Competition runs on certification and traceability, clinical evidence, channel reach, brand trust, and breadth of formats.
| Company | HQ | Tier | Footprint | Positioning note |
|---|---|---|---|---|
| Comvita Ltd. | Te Puke, NZ | Global leader | 40+ countries | Medihoney range across hospitals, pharmacy and DTC. ~NZD 180M revenue in 2025; medical wound-care division ~35%. Pioneered blockchain traceability in 2024. |
| Manuka Health NZ | New Zealand | Tier 1 | AU, DE, UK, US | MGO-rated range across consumer wellness and clinical wound care. Strong pharmacy presence. |
| Capilano Honey | Australia | Tier 1 | AU, AsiaPac | Australia's largest honey company; expanding medical-grade range with strong national distribution. |
| Wedderspoon Organic | United States | Tier 1 (consumer) | US, CA | Leading North-American consumer Manuka brand. Proprietary K-Factor certification; premium DTC and natural-health retail positioning. |
| Steens Ltd. | New Zealand | Premium specialist | Global, selective | Ultra-raw Manuka processing — preserved bioactive spectrum, premium consumer and clinical positioning. |
| Rowse Honey | United Kingdom | Tier 2 | UK, EU | Expanding medical-grade portfolio with growing presence in NHS-supplied wound-care products. |
| Triticum / L-Mesitran | Maastricht, NL | Clinical specialist | EU, UK, ROW | Supplemented MGH range — ointment, soft gel, hydro, tulle, foam — embedded in NL and UK wound-care guidelines. |
| Bee Maid Honey | Canada | Tier 2 | NA | Beekeeper cooperative supplying both consumer and institutional channels in North America. |
| Apis Flora | Brazil | Regional leader | LATAM | Notable LATAM emerging player; therapeutic honey varieties from Brazilian biodiversity. |
Clinician note
NPA 10+ is the clinical floor. NPA 15+ for infected or biofilm-forming wounds.
NPA 5–10
Skin care, consumer wellness, lozenges and syrups.
NPA 10–15 · 263–514 mg/kg MGO
Working clinical floor for chronic wound management (WUWHS, AWMA).
NPA 15–20+ · 514–829 mg/kg MGO
Infected, sloughy or biofilm-forming wounds, burns and sinus.
FDA / TGA-registered medical devices must hold standardised MGO content batch to batch — a guarantee unregistered consumer honey does not provide.
Sources & methodology
A synthesis across multiple analyst houses — not a single republished report.
The figures on this page are a paraphrased synthesis of publicly available analyst coverage of the medical-grade honey category. Estimates differ between firms; numbers here represent the central range across published sources, not the exact figures of any one provider. Where a single house is the outlier, the consensus is preferred.
Industry analysts (market sizing)
- · Dataintelo — Global Medical Grade Honey Market 2025–2034
- · Grand View Research — Medical Grade Honey Market Size & Share Report
- · Fortune Business Insights — Medical Grade Honey Market
- · Mordor Intelligence — Medical Grade Honey Market Outlook
- · Polaris Market Research — Medical Grade Honey Market
Primary & clinical context
- · IDF Diabetes Atlas — diabetes & DFU prevalence
- · WHO & ECDC — AMR burden
- · IWGDF — diabetic foot ulcer guidelines
- · NICE / BNF — UK formulary positioning
- · WUWHS & EWMA — wound-care consensus documents
- · Comvita, Manuka Health, Capilano, Triticum — published annual reports & investor disclosures
Editorial note. All figures, tables and commentary on this page are paraphrased from publicly available sources and represent independent editorial synthesis. No charts, tables or verbatim text have been reproduced from any single proprietary report. Figures are directional — for a defensible, indication-specific market view (e.g. for an investment memo, regulatory filing or board paper), commission a tailored briefing.